484 related articles for article (PubMed ID: 18424792)
1. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
2. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
[TBL] [Abstract][Full Text] [Related]
3. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
[TBL] [Abstract][Full Text] [Related]
4. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
7. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Jansen WT; Verel A; Verhoef J; Milatovic D
Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
13. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
Mendes RE; Sader HS; Jones RN
Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
15. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
16. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
17. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
King A; Phillips I; Kaniga K
J Antimicrob Chemother; 2004 May; 53(5):797-803. PubMed ID: 15028667
[TBL] [Abstract][Full Text] [Related]
19. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
